Singapore markets close in 7 hours 51 minutes
  • Straits Times Index

    3,280.04
    -7.91 (-0.24%)
     
  • Nikkei

    27,717.55
    -539.70 (-1.91%)
     
  • Hang Seng

    24,112.78
    -105.25 (-0.43%)
     
  • FTSE 100

    7,563.55
    -47.68 (-0.63%)
     
  • BTC-USD

    42,287.11
    -74.22 (-0.18%)
     
  • CMC Crypto 200

    1,007.40
    -1.98 (-0.20%)
     
  • S&P 500

    4,577.11
    -85.74 (-1.84%)
     
  • Dow

    35,368.47
    -543.34 (-1.51%)
     
  • Nasdaq

    14,506.90
    -386.86 (-2.60%)
     
  • Gold

    1,812.80
    +0.40 (+0.02%)
     
  • Crude Oil

    86.83
    +1.40 (+1.64%)
     
  • 10-Yr Bond

    1.8650
    +0.0930 (+5.25%)
     
  • FTSE Bursa Malaysia

    1,542.92
    -12.41 (-0.80%)
     
  • Jakarta Composite Index

    6,614.06
    -30.99 (-0.47%)
     
  • PSE Index

    7,343.96
    +120.13 (+1.66%)
     

J&J scraps late-stage study testing Stelara for lupus

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the NYSE in New York
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) - Johnson & Johnson's Janssen unit said on Friday it would discontinue a late-stage study testing its psoriatic arthritis drug Stelara as a treatment for lupus as it was not found to be effective against the auto-immune disease.

Systemic Lupus Erythematosus, or lupus, causes inflammation in connective tissues, such as cartilage and the lining of blood vessels.

A second late-stage study to be conducted in China was planned but will not start given this decision, the company said.

Stelara, which blocks two inflammation-causing proteins IL-12 and IL-23, is one of J&J's largest revenue generators, bringing in sales of about $1.82 billion in first quarter this year.

The drug is approved in the United States to treat the skin condition scaly plaque psoriasis, a type of arthritis associated with psoriasis and Crohn's disease.

(Reporting by Manojna Maddipatla and Dania Nadeem in Bengaluru; Editing by Saumyadeb Chakrabarty)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting